TIDMPRTC
RNS Number : 5374A
PureTech Health PLC
30 May 2019
30 May 2019
PureTech Health plc
Results of Annual General Meeting
The Annual General Meeting of PureTech Health plc (LSE: PRTC)
("PureTech Health" or the "Company"), was held at 3.00 pm BST on
Wednesday 29 May 2019. All of the resolutions proposed at the
Annual General Meeting were duly passed by the shareholders on a
poll.
The results of the poll, incorporating the proxy votes lodged in
advance of the meeting, are set out below. All resolutions were
passed by greater than 90% of the shares voted at the meeting.
Resolutions For % Against % Withheld Total
votes
cast
001. To approve
the Company's
Annual Report
and Accounts for
year ended 31
December 2018 210,215,060 100.00 0 0.00 0 210,215,060
------------ ------- ----------- ----- ---------- ------------
002. To approve
the Directors'
Remuneration Report 198,555,876 94.45 11,659,058 5.55 125 210,214,934
------------ ------- ----------- ----- ---------- ------------
003. To approve
the Directors'
Remuneration Policy 209,293,335 99.56 920,331 0.44 1,393 210,213,666
------------ ------- ----------- ----- ---------- ------------
004. To elect
Mr. Joichi Ito
as a director 210,215,060 100.00 0 0.00 0 210,215,060
------------ ------- ----------- ----- ---------- ------------
005. To elect
Dr. Raju Kucherlapati
as a director 208,496,306 99.18 1,718,754 0.82 0 210,215,060
------------ ------- ----------- ----- ---------- ------------
006. To elect
Dr. John LaMattina
as a director 208,003,184 98.95 2,211,876 1.05 0 210,215,060
------------ ------- ----------- ----- ---------- ------------
007. To elect
Dame Marjorie
Scardino as a
director 210,140,788 100.00 8,010 0.00 66,261 210,148,798
------------ ------- ----------- ----- ---------- ------------
008. To elect
Mr. Christopher
Viehbacher as
a director 210,215,060 100.00 0 0.00 0 210,215,060
------------ ------- ----------- ----- ---------- ------------
009. To elect
Dr. Robert Langer
as a director 209,713,927 99.76 501,132 0.24 0 210,215,059
------------ ------- ----------- ----- ---------- ------------
010. To elect
Dr. Bennett Shapiro
as a director 194,031,490 92.88 14,882,202 7.12 1,301,367 208,913,692
------------ ------- ----------- ----- ---------- ------------
011. To elect
Ms. Daphne Zohar
as a director 210,215,060 100.00 0 0.00 0 210,215,060
------------ ------- ----------- ----- ---------- ------------
012. To elect
Mr. Stephen Muniz
as a director 210,215,060 100.00 0 0.00 0 210,215,060
------------ ------- ----------- ----- ---------- ------------
013. To reappoint
KPMG LLP as Auditors
of the Company 210,212,422 100.00 2,638 0.00 0 210,215,060
------------ ------- ----------- ----- ---------- ------------
014. To authorise
the Audit Committee
to determine the
Auditors' remuneration 210,215,060 100.00 0 0.00 0 210,215,060
------------ ------- ----------- ----- ---------- ------------
015. To authorise
the allotment
of shares 209,756,819 99.78 458,241 0.22 0 210,215,060
------------ ------- ----------- ----- ---------- ------------
016. To dis-apply
pre-emption rights 210,208,060 100.00 2,000 0.00 5,000 210,210,060
------------ ------- ----------- ----- ---------- ------------
017. To further
dis-apply pre-emption
rights for acquisitions
and specified
capital investments. 202,061,471 96.12 8,148,589 3.88 5,000 210,210,060
------------ ------- ----------- ----- ---------- ------------
018. To authorise
market purchase
of own shares 206,712,422 98.33 3,502,638 1.67 0 210,215,060
------------ ------- ----------- ----- ---------- ------------
019. To authorise
general meetings
to be called on
not less than
14 clear days'
notice 209,617,985 99.72 592,075 0.28 5,000 210,210,060
------------ ------- ----------- ----- ---------- ------------
Due to its shareholding in the Company, Invesco Asset Management
Limited is deemed to be a controlling shareholder as defined in the
Financial Conduct Authority's Listing Rules. Accordingly, each
resolution to elect an independent director (resolutions 5, 6, 7
and 8) has under Listing Rule 9.2.2E been approved by a majority of
the votes cast by:
-- the shareholders of the Company as a whole; and
-- the independent shareholders of the Company, that is, all the
shareholders entitled to vote on each resolution excluding the
controlling shareholder as shown below.
Resolutions For % Against % Withheld Total
votes
cast
005. To elect
Dr. Raju Kucherlapati
as a director 118,334,309 98.57 1,718,754 1.43 0 120,053,063
------------ ------- ---------- ----- --------- ------------
006. To elect
Dr. John LaMattina
as a director 117,841,187 98.16 2,211,876 1.84 0 120,053,063
------------ ------- ---------- ----- --------- ------------
007. To elect
Dame Marjorie
Scardino as a
director 119,978,791 99.99 8,010 0.01 66,261 119,986,801
------------ ------- ---------- ----- --------- ------------
008. To elect
Mr. Christopher
Viehbacher as
a director 120,053,063 100.00 0 0.00 0 120,053,063
------------ ------- ---------- ----- --------- ------------
Notes:
(1) A vote "Withheld" is not a vote in law and is not counted in
the calculation of the votes "For" or "Against" a resolution.
(2) As at 28 May 2019, the number of issued shares in the
Company was 282,493,867 ordinary shares, which was the total number
of shares entitling the holders to attend and vote for or against
all the resolutions at the AGM. In accordance with the Company's
Articles of Association, on a poll every member present in person
or by proxy has one vote for every share held.
(3) The full text of the resolutions may be found in the Notice
of the Annual General Meeting, copies of which are available on
both the Company's website www.puretechhealth.com/ and on the
National Storage Mechanism.
(4) In accordance with Listing Rule 9.6.2, a copy of the
resolutions, other than those concerning ordinary business has been
submitted to the National Storage Mechanism and will shortly be
available for inspection at: www.morningstar.co.uk/uk/NSM.
About PureTech Health
PureTech Health (LSE: PRTC) is an advanced biopharmaceutical
company developing BIG medicines for dysfunctions of the
Brain-Immune-Gut axis. The Company has gained deep insights into
the connection between these systems and the resulting role in
diseases that have proven resistant to established therapeutic
approaches. By harnessing this emerging field of human biology,
PureTech Health is developing new categories of medicines with the
potential to have great impact on people with serious diseases.
PureTech Health is advancing a rich pipeline of innovative
therapies with an unbiased, non-binary, and capital efficient
R&D model across its affiliates and its internal labs.
PureTech's affiliates include seven clinical-stage platforms,
including one product that has been cleared by the US Food and Drug
Administration (FDA) and a second product candidate that has been
filed with the FDA for review, and several other novel preclinical
programmes. The PureTech Health pipeline includes ground-breaking
platforms and therapeutic candidates that were developed in
collaboration with some of the world's leading experts.
PureTech's internal research and development is centred on
tissue-selective immunomodulation for the treatment of oncology,
autoimmune, and CNS-related disorders, with a near-term focus on
targeting newly-discovered, foundational immunosuppressive
mechanisms in oncology and novel approaches that harness the
lymphatic infrastructure.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Forward Looking Statement
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company's future prospects, developments and strategies. The
forward-looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, those risks and uncertainties described in the risk factors
included in the regulatory filings for PureTech Health plc. These
forward-looking statements are based on assumptions regarding the
present and future business strategies of the company and the
environment in which it will operate in the future. Each
forward-looking statement speaks only as at the date of this press
release. Except as required by law and regulatory requirements,
neither the company nor any other party intends to update or revise
these forward-looking statements, whether as a result of new
information, future events or otherwise.
Contact:
Investors EU media US media
Allison Mead Talbot Ben Atwell, Rob Winder Tom Donovan
+1 617 651 3156 +44 (0) 20 3727 1000 +1 857 559 3397
amt@puretechhealth.com ben.atwell@FTIconsulting.com tom@tenbridgecommunications.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
RAGCKCDKKBKBOPB
(END) Dow Jones Newswires
May 30, 2019 02:00 ET (06:00 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Apr 2024 to May 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From May 2023 to May 2024